Peptide manufacturing needs to grow to ten times today's output within five years, driven by GLP-1s and other peptide therapies. For Dr. Abdelaziz Toumi, meeting demand on that scale takes alliances built for the whole modality, not for one company.
Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto
This week on Making It In Manufacturing, William Keutenius sat down with Dr. Abdelaziz Toumi, CEO of Lupin Manufacturing Solutions, Lupin's CDMO business, at CPHI Milan 2026, where ARTO was the official podcast partner.
In this episode, Abdel covers:
(01:44) Why Lupin Manufacturing Solutions did not start from scratch: R&D and manufacturing built over many years, sites approved by the US FDA, EMA and WHO, and the service mindset a CDMO needs, where it is all about speed and time.
(03:12) Building a coherent global team with a culture of customer centricity, and why the decisions you make today on modality, chemistry, digitalisation and automation shape the network you will have in five to ten years.
(04:32) How a CDMO earns the trust of new customers: listen first, understand the problem, then find a better solution, as with peptides, where the bottleneck turned out to be upstream and downstream as well as in drug substance.
(06:04) Why being close to customers in the US and Europe matters, and why business development is only one way to do it: programme management in the same time zone means you can pick up the phone, sit down together and solve problems face to face.
(07:54) How the alliance with PolyPeptide works: Lupin's DNA in large-scale chemical synthesis, peptide demand driven by GLP-1s, the need for supply chain resilience, and an arrangement built to help innovators and other CDMOs move fast on building blocks.
(11:26) Where Lupin Manufacturing Solutions invests next: scaling its building block business, a new payload-linker investment at its Vizag facility, and deeper work in ADCs and peptides, two areas of hyper growth within its core capabilities.
(13:10) The one thing he would change to make the industry better: don't think you can do everything alone. In his words, one plus one equals three.
Recorded on the final day of the show, this conversation is a clear look at how a CDMO built on the foundations of a global healthcare company wins new customers and chooses where to invest next. Watch the full episode to hear why Abdel believes events like CPHI exist for exactly this: finding the partners who complement you.
Follow ARTO
LinkedIn: https://www.linkedin.com/company/artotalent/
Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng
Instagram: https://www.instagram.com/arto.talent
TikTok: https://www.tiktok.com/@artotalent
Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575
Website: https://arto-talent.com/
Youtube: https://www.youtube.com/@artotalent
Dr. Abdelaziz Toumi
LinkedIn: https://www.linkedin.com/in/abdelaziztoumi/
Timestamps:
00:00 Introduction
01:09 Lupin and Lupin Manufacturing Solutions
01:44 A CDMO built on Lupin's foundations
03:12 Building a coherent global team
04:32 Earning the trust of new customers
06:04 Being close to customers in the US and Europe
07:54 How the PolyPeptide alliance works
10:17 What's next for Lupin Manufacturing Solutions
11:26 The next investments: ADCs and peptides
13:10 One thing to make the industry better
#MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #CDMO #Peptides #ADC #PharmaManufacturing #PharmaSupplyChain
","author_name":"ARTO Talent"}